Junbao Du Selected Research

Postural Orthostatic Tachycardia Syndrome

1/2021	Baseline Corrected QT Interval Dispersion Is Useful to Predict Effectiveness of Metoprolol on Pediatric Postural Tachycardia Syndrome.
1/2019	Heart Rate Variability Predicts Therapeutic Response to Metoprolol in Children With Postural Tachycardia Syndrome.
1/2018	Plasma Homocysteine Level in Children With Postural Tachycardia Syndrome.
12/2017	Serum Resistin Negatively Correlates with Clinical Severity of Postural Tachycardia Syndrome in Children.
4/2017	Recent advances in the understanding of the mechanisms underlying postural tachycardia syndrome in children: practical implications for treatment.
1/2017	Hemocytometric Measures Predict the Efficacy of Oral Rehydration for Children with Postural Tachycardia Syndrome.
10/2016	Body Mass Index (BMI) is Associated with the Therapeutic Response to Oral Rehydration Solution in Children with Postural Tachycardia Syndrome.
9/2015	[Relationship between 24-hour urinary sodium and renin-angiotensin-aldosterone system in children with postural tachycardia syndrome].
6/2015	[Diastolic and therapeutic value of biomarkers in children with postural tachycardia syndrome].
6/2015	Total peripheral vascular resistance, cardiac output, and plasma C-type natriuretic Peptide level in children with postural tachycardia syndrome.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Junbao Du Research Topics

Disease

28	Postural Orthostatic Tachycardia Syndrome 01/2021 - 01/2011
12	Pulmonary Hypertension 01/2022 - 09/2002
11	Inflammation (Inflammations) 01/2022 - 04/2014
11	Vasovagal Syncope 01/2022 - 04/2008
10	Hypertension (High Blood Pressure) 01/2022 - 02/2003
6	Cardiovascular Diseases (Cardiovascular Disease) 09/2022 - 05/2004
6	Mucocutaneous Lymph Node Syndrome (Kawasaki Disease) 01/2022 - 01/2015
6	Vascular Calcification 01/2022 - 01/2003
6	Syncope (Fainting) 01/2022 - 04/2008
6	Hypertrophy 01/2022 - 01/2002
6	Hypoxia (Hypoxemia) 01/2021 - 01/2002
5	Atherosclerosis 01/2022 - 04/2011
5	Vascular Remodeling 11/2021 - 09/2002
4	Acute Lung Injury 01/2022 - 09/2008
3	Hypotension (Low Blood Pressure) 01/2022 - 07/2003
3	Brain Injuries (Brain Injury) 01/2022 - 02/2018
3	Body Weight (Weight, Body) 01/2022 - 10/2008
3	Epilepsy (Aura) 01/2022 - 02/2018
3	Myocardial Ischemia (Ischemic Heart Diseases) 01/2021 - 11/2013
3	Febrile Seizures (Febrile Seizure) 02/2006 - 02/2005
2	Vascular Diseases (Vascular Disease) 01/2022 - 03/2004
2	Pulmonary Arterial Hypertension 12/2020 - 07/2010
2	Seizures (Absence Seizure) 02/2018 - 02/2018
2	Nervous System Diseases (Neurological Disorders) 02/2018 - 02/2018
2	Ischemia 11/2013 - 02/2009
2	Hyperhomocysteinemia 05/2010 - 12/2003
2	Shock 08/2003 - 07/2003
2	Septic Shock (Toxic Shock Syndrome) 08/2003 - 07/2003
1	Osteosarcoma (Osteogenic Sarcoma) 07/2022
1	Neoplasm Metastasis (Metastasis) 07/2022
1	Pathologic Processes 01/2022
1	Colitis 01/2022
1	Cardiomyopathies (Cardiomyopathy) 01/2022
1	Congenital Heart Defects (Congenital Heart Defect) 01/2022
1	Fibrosis (Cirrhosis) 01/2022
1	Fever (Fevers) 01/2022
1	Sepsis (Septicemia) 01/2022
1	Exanthema (Rash) 01/2022
1	Cardiotoxicity 01/2022

Drug/Important Bio-Agent (IBA)

27	Hydrogen Sulfide (Sulfide, Hydrogen)IBA 09/2022 - 08/2003
14	Sulfur DioxideIBA 01/2022 - 02/2009
11	Metoprolol (Toprol-XL)FDA LinkGeneric 01/2022 - 04/2008
9	Midodrine (Midon)FDA LinkGeneric 06/2015 - 01/2011
8	SaltsIBA 01/2021 - 08/2012
6	Intravenous Immunoglobulins (IVIG)FDA Link 01/2022 - 08/2015
6	CollagenIBA 01/2021 - 09/2002
6	sodium bisulfide (NaHS)IBA 06/2015 - 02/2003
5	Aspartate Aminotransferases (Aspartate Transaminase)IBA 01/2022 - 02/2015
5	SodiumIBA 01/2022 - 08/2012
5	Biomarkers (Surrogate Marker)IBA 10/2015 - 08/2014
4	EnzymesIBA 07/2022 - 10/2003
4	MonocrotalineIBA 01/2022 - 10/2016
4	Carbon MonoxideIBA 01/2017 - 01/2003
4	AdrenomedullinIBA 06/2015 - 07/2003
3	GasotransmittersIBA 01/2022 - 02/2015
3	Pharmaceutical PreparationsIBA 01/2022 - 02/2018
3	DNA (Deoxyribonucleic Acid)IBA 01/2021 - 04/2014
3	Proteins (Proteins, Gene)FDA Link 01/2021 - 01/2017
3	Biological ProductsIBA 01/2020 - 02/2003
3	Brain Natriuretic Peptide (Natrecor)FDA Link 06/2019 - 05/2013
3	Oleic Acid (Oleate)IBA 11/2017 - 09/2008
3	ORALIT (ORS)IBA 01/2017 - 01/2015
3	SolutionsIBA 10/2016 - 10/2003
3	Nicotine FDA Link 02/2016 - 01/2003
3	Cholecalciferol (Vitamin D3)FDA Link 02/2016 - 01/2003
3	C-Type Natriuretic Peptide (Peptide, C-Type Natriuretic)IBA 06/2015 - 07/2003
2	SulfurIBA 01/2022 - 01/2018
2	C-Reactive ProteinIBA 01/2022 - 06/2019
2	PotassiumIBA 01/2022 - 01/2018
2	Nitric Oxide (Nitrogen Monoxide)FDA Link 11/2021 - 08/2003
2	Taurine FDA Link 01/2021 - 05/2004
2	Angiotensin IIIBA 01/2021 - 12/2016
2	Intercellular Adhesion Molecule-1 (Intercellular Adhesion Molecule 1)IBA 01/2021 - 02/2009
2	Sildenafil Citrate (Viagra)FDA Link 12/2020 - 07/2010
2	AntioxidantsIBA 10/2020 - 01/2017
2	Interleukin-6 (Interleukin 6)IBA 01/2020 - 09/2008
2	Cysteine (L-Cysteine)FDA Link 10/2019 - 04/2014
2	CystathionineIBA 10/2019 - 01/2017
2	Bosentan (Tracleer)FDA Link 01/2019 - 07/2010
2	Erythropoietin FDA Link 02/2018 - 02/2018
2	HomocysteineIBA 01/2018 - 12/2003
2	oxidized low density lipoproteinIBA 04/2014 - 06/2010
2	Adrenergic Receptors (Adrenergic Receptor)IBA 01/2011 - 07/2009
2	urotensin IIIBA 03/2004 - 01/2002
2	Heme Oxygenase (Decyclizing) (Heme Oxygenase)IBA 12/2003 - 01/2003
2	Messenger RNA (mRNA)IBA 12/2003 - 10/2003
2	EndotoxinsIBA 08/2003 - 07/2003
1	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2022
1	Amino Acids FDA Link 01/2022
1	Alanine Transaminase (SGPT)IBA 01/2022
1	gamma-Glutamyltransferase (gamma-Glutamyl Transpeptidase)IBA 01/2022
1	AnthracyclinesIBA 01/2022
1	BilirubinIBA 01/2022
1	Prealbumin (Transthyretin)IBA 01/2022
1	NG-Nitroarginine Methyl Ester (L-NAME)IBA 11/2021

Therapy/Procedure

8	Therapeutics 01/2022 - 04/2008
3	Drug Therapy (Chemotherapy) 01/2020 - 01/2014
3	Fluid Therapy (Oral Rehydration Therapy) 01/2017 - 01/2015
1	Intravenous Injections 01/2022
1	Duration of Therapy 01/2022